Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14179-14190

  Li, Lei ^a,b   Dang, Qiang ^a,b   Xie, Hongjun ^a,b   Yang, Zhao ^a   He, Dalin ^a   Liang, Liang ^a,b   Song, Wenbing ^a,b   Yeh, Shuyuan ^b   Chang, Chawnshang ^b,c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Androgen receptor; HOTAIR PRC2; Mast cells; Prostate cancer; Stem cells

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; ENZALUTAMIDE; GELATINASE B; ANILIDE; AR PROTEIN, HUMAN; HOTAIR LONG UNTRANSLATED RNA, HUMAN; LONG UNTRANSLATED RNA; MMP9 PROTEIN, HUMAN; NITRILE; PHENYLTHIOHYDANTOIN; TOLUENESULFONIC ACID DERIVATIVE;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL COUNT; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MATURATION; CELL MIGRATION; CELL POPULATION; CELL RENEWAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAST CELL; METASTASIS; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; STEM CELL; TUMOR INVASION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CANCER STEM CELL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFECTS; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANILIDES; ANIMALS; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MAST CELLS; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NITRILES; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RNA, LONG NONCODING; TOSYL COMPOUNDS;

EID: 84931089661     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3651     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Chang CS, Kokontis J and Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science. 1988; 240:324-326.
3. Heinlein CA and Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004; 25:276-308.
4. Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, Chuang KH, Huang SP, Lardy H and Chang C. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:12188-12193.
5. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ and Chang C. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene. 2010; 29:3593-3604.
6. Chang C, Lee SO, Yeh S and Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2013.
7. Ammirante M, Luo JL, Grivennikov S, Nedospasov S and Karin M. B-cell-derived lymphotoxin promotes castrationresistant prostate cancer. Nature. 2010; 464:302-305.
8. Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ and Chang C. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med. 2013; 5:1383-1401.
9. Liotta LA and Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001; 411:375-379.
10. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB and Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007; 13:1211-1218.
11. Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F, Lee DM, Zhang G, Glickman JN, Shin K, Rao VP, Poutahidis T, Weissleder R, McNagny KM and Khazaie K. Mast cells are an essential hematopoietic component for polyp development. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:19977-19982.
12. Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, Stattin P, Egevad L, Granfors T, Wikstrom P and Bergh A. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol. 2010; 177:1031-1041.
13. Franck-Lissbrant I, Haggstrom S, Damber JE and Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology. 1998; 139:451-456.
14. Zhang Q, Yang M, Shen J, Gerhold LM, Hoffman RM and Xing HR. The role of the intravascular microenvironment in spontaneous metastasis development. Int J Cancer. 2010; 126:2534-2541.
15. Mueller MT, Hermann PC and Heeschen C. Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci (Elite Ed). 2010; 2:602-613.
16. Pfeiffer MJ and Schalken JA. Stem cell characteristics in prostate cancer cell lines. Eur Urol. 2010; 57(2):246-254.
17. Maitland NJ and Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol. 2008; 26:2862-2870.
18. Lee SO, Ma Z, Yeh CR, Luo J, Lin TH, Lai KP, Yamashita S, Liang L, Tian J, Li L, Jiang Q, Huang CK, Niu Y, Yeh S and Chang C. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol. 2013; 5:14-26.
19. Yoo KH and Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci. 2012;8:59-65.
20. Chase A and Cross NC. Aberrations of EZH2 in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:2613-2618.
21. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E and Chang HY. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007; 129:1311-1323.
22. Woo CJ and Kingston RE. HOTAIR lifts noncoding RNAs to new levels. Cell. 2007; 129:1257-1259.
23. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E and Chang HY. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010; 329:689-693.
24. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464:1071-1076.
25. Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, Yeh SD, Fujimoto N, Yeh S and Chang C. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus antiandrogen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem. 2013; 288:19359-19369.
26. Visvader JE and Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8:755-768.
27. Crivellato E, Beltrami C, Mallardi F and Ribatti D. Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. Br J Haematol. 2003; 123:19-21.
28. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB and Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer research. 1998; 58:5310-5314.
29. Tian J, Lee SO, Liang L, Luo J, Huang CK, Li L, Niu Y and Chang C. Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis. J Biol Chem. 2012; 287:39954-39966.
30. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A and Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castrationresistant prostate cancer displaying bone flare discordant with serologic response. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:4854-4861.
31. Cooperberg MR, Vickers AJ, Broering JM and Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010; 116:5226-5234.
32. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J and Johnson L. Androgen deprivation causes epithelialmesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer research. 2012; 72:527-536.
33. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S and Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:12182-12187.
34. Zudaire E, Martinez A, Garayoa M, Pio R, Kaur G, Woolhiser MR, Metcalfe DD, Hook WA, Siraganian RP, Guise TA, Chirgwin JM and Cuttitta F. Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol. 2006; 168:280-291.
35. Zhan Y, Cao B, Qi Y, Liu S, Zhang Q, Zhou W, Xu D, Lu H, Sartor O, Kong W, Zhang H and Dong Y. Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer. Int J Cancer. 2013; 133:2225-2233.
36. Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC and Chang C. Tissue prostatespecific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer research. 2008; 68:7110-7119.
37. Liu NC, Lin WJ, Yu IC, Lin HY, Liu S, Lee YF and Chang C. Activation of TR4 orphan nuclear receptor gene promoter by cAMP/PKA and C/EBP signaling. Endocrine. 2009; 36:211-217.
38. Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E, Chen YT, Hu YC, Wang L, Chuang KH, Wu CT and Chang C. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem. 2005; 280:33558-33565.